 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE:ADCT, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates ADCs for patients with hematological malignancies and solid tumors, today announced completion of enrollment in the pivotal Phase 2 clinical trial evaluating the efficacy and safety of camidanlumab tesirine Cami, formerly ADCT-301 in patients with relapsed 